Conference Coverage

Care for patients with gout needs improvement, says doctor


 

AT INTERNAL MEDICINE 2023

Management of advanced gout

“The management of advanced gout is challenging, and the dissolution of MSU is slow unless you take an aggressive approach,” Dr. Edwards said.

Switching to pegloticase is recommended for patients with frequent flares, nonresolving tophi, or high serum urate levels that persist despite treatment with xanthine oxidase inhibitors or other ULT agents.

“The frequency and severity of gout flares are what patients focus on, but if that’s the only focus of the treating physicians, then they are leaving the job less than halfway done. Getting the serum urate to below a level of 6.0 mg/dL is the most important aspect in the lifelong management of gout,” said Dr. Edwards.

Barriers to effective gout treatment

When asked during an interview after the session about the most important barriers to successful gout management, Allison M. Mays, MD, a geriatric medicine subspecialist at Cedars-Sinai Medical Center, Los Angeles, said that “the fact that gout mostly impacts quality of life and not necessarily mortality means that other things may take precedent.” She explained that gout typically coexists with other comorbidities, often multiple ones. Patients may also defer taking an additional medication for a disease like gout, which has only episodic discomfort.

She added that gout management involves shared decision-making between patients and the medical team – including the primary care physician, rheumatologist, orthopedist, and emergency physician. Following a visit to the urgent care or the ED for an acute flare of gout, the patient may not follow up with their primary care doctor or bring it up at their next visit for chronic management, she noted.

Dr. Edwards serves as a consultant to Horizon Pharmaceuticals, Atom Biosciences, Shanton Biosciences, and Aclaris Therapeutics. Horizon marketed pegloticase up until last month when Amgen bought the drug. Dr. Edwards is also president of Gout Education Society, and he has no financial agreement with any of the multiple companies that produce colchicine and allopurinol. Dr. Mays reported no conflicts.

Pages

Recommended Reading

Antiphospholipid antibodies linked to future CV events
Federal Practitioner
New 46-week PsA data released for IL-17A inhibitor izokibep
Federal Practitioner
Metformin linked to reduced osteoarthritis risk
Federal Practitioner
Registry data ‘reassure’ on biologics’ heart attack risk in rheumatoid arthritis
Federal Practitioner
Meta-analysis examines cancer risk concern for JAK inhibitors
Federal Practitioner
NSAID use may mask MRI findings in a quarter of spondyloarthritis cases
Federal Practitioner
Can you spot hypermobility spectrum disorder?
Federal Practitioner
Long-COVID rate may be higher with rheumatic diseases
Federal Practitioner
FDA fast tracks potential CAR T-cell therapy for lupus
Federal Practitioner
Normal CRP during RA flares: An ‘underappreciated, persistent phenotype’
Federal Practitioner